Daiwa Securities Group Inc. Has $100,000 Position in Alnylam Pharmaceuticals Inc. (ALNY)
Daiwa Securities Group Inc. continued to hold its stake in shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,800 shares of the biopharmaceutical company’s stock at the end of the second quarter. Daiwa Securities Group Inc.’s holdings in Alnylam Pharmaceuticals were worth $100,000 as of its most recent SEC filing.
A number of other large investors have also recently modified their holdings of ALNY. Wellington Management Group LLP increased its stake in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock valued at $749,826,000 after buying an additional 1,288,123 shares during the period. State Street Corp boosted its position in Alnylam Pharmaceuticals by 15.7% in the first quarter. State Street Corp now owns 1,936,520 shares of the biopharmaceutical company’s stock valued at $121,553,000 after buying an additional 262,783 shares in the last quarter. BlackRock Fund Advisors boosted its position in Alnylam Pharmaceuticals by 6.5% in the first quarter. BlackRock Fund Advisors now owns 1,838,376 shares of the biopharmaceutical company’s stock valued at $115,395,000 after buying an additional 112,252 shares in the last quarter. Slate Path Capital LP boosted its position in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock valued at $71,244,000 after buying an additional 410,000 shares in the last quarter. Finally, Bridger Management LLC bought a new position in Alnylam Pharmaceuticals during the first quarter valued at $50,041,000. Institutional investors and hedge funds own 85.96% of the company’s stock.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) traded up 3.65% during mid-day trading on Monday, hitting $35.52. 2,680,561 shares of the company traded hands. The firm has a 50 day moving average of $70.69 and a 200 day moving average of $66.05. The firm’s market capitalization is $3.04 billion. Alnylam Pharmaceuticals Inc. has a one year low of $33.16 and a one year high of $110.75.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.19. The business had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.85) earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals Inc. will post ($4.68) earnings per share for the current fiscal year.
Several research analysts have weighed in on the stock. Cowen and Company reissued an “outperform” rating and issued a $100.00 price target (down from $150.00) on shares of Alnylam Pharmaceuticals in a report on Saturday. Piper Jaffray Cos. set a $106.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. Morgan Stanley cut shares of Alnylam Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $38.00 to $36.00 in a report on Friday. FBR & Co lowered their price target on shares of Alnylam Pharmaceuticals from $180.00 to $100.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Goldman Sachs Group Inc. lowered their price target on shares of Alnylam Pharmaceuticals from $65.00 to $34.00 and set a “neutral” rating on the stock in a report on Thursday. Eight research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $80.88.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the business’s stock in a transaction dated Wednesday, July 20th. The shares were sold at an average price of $64.69, for a total value of $1,950,468.19. Following the transaction, the chief executive officer now directly owns 148,465 shares in the company, valued at $9,604,200.85. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.00% of the stock is currently owned by company insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.